即将过去的2025年,生物医药研发失败的暗礁轮廓格外清晰。从肿瘤免疫的明星靶点TIGIT,到攻克阿尔茨海默病,再到高风险高回报的罕见病领域,乃至免疫、精神等成熟赛道,全球药企接连遭遇了里程碑式的研发挫折。这些失败不仅耗费了巨额研发资金,导致了合作解体、管线关闭、公司清退重组,更映照出人类挑战复杂疾病的科学认知边界与转化医学的艰难鸿沟。《新康界》对2025年的关键研发败局进行梳理,以期为行业未来的...
Source Link即将过去的2025年,生物医药研发失败的暗礁轮廓格外清晰。从肿瘤免疫的明星靶点TIGIT,到攻克阿尔茨海默病,再到高风险高回报的罕见病领域,乃至免疫、精神等成熟赛道,全球药企接连遭遇了里程碑式的研发挫折。这些失败不仅耗费了巨额研发资金,导致了合作解体、管线关闭、公司清退重组,更映照出人类挑战复杂疾病的科学认知边界与转化医学的艰难鸿沟。《新康界》对2025年的关键研发败局进行梳理,以期为行业未来的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.